| http://www.w3.org/ns/prov#value | - Post-marketing surveillance reports indicate that TNF-blockers such as infliximab, etanercept, adalimumab, certolizumab, and golimumab increase the risk of haematological and other cancers and psoriasis in children, adolescents, and adults.
|
